CA2275438A1 - Methodes ameliorees de transduction cellulaire - Google Patents

Methodes ameliorees de transduction cellulaire Download PDF

Info

Publication number
CA2275438A1
CA2275438A1 CA002275438A CA2275438A CA2275438A1 CA 2275438 A1 CA2275438 A1 CA 2275438A1 CA 002275438 A CA002275438 A CA 002275438A CA 2275438 A CA2275438 A CA 2275438A CA 2275438 A1 CA2275438 A1 CA 2275438A1
Authority
CA
Canada
Prior art keywords
cell
cells
composition
tumor
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002275438A
Other languages
English (en)
Inventor
Isaiah J. Fidler
Zhongyun Dong
Rakesh Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2275438A1 publication Critical patent/CA2275438A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Compositions et méthodes pour inhiber l'expression et/ou l'activité de l'interféron-.beta. endogène dans des cellules ciblées pour une transduction avec des vecteurs viraux, en particulier avec des vecteurs d'adénovirus. L'invention concerne par conséquent également des méthodes de thérapie génique améliorées pour des maladies génétiques. L'invention porte également sur des méthodes de traitement des maladies liées à une néovascularisation, par exemple le cancer, par la production in vivo d'angiostatine inhibant la formation nouveaux vaisseaux sanguins. Dans des modes de réalisation particuliers, ce résultat est obtenu par transduction de macrophages ex vivo avec un gène GM-CSF, induisant la sécrétion de métallo-élastase de macrophage, laquelle convertit le plasminogène en angiostatine. Une fois administrés, les macrophages transduits se dirigent naturellement vers les sites tumoraux, réalisant un ciblage efficace de l'effet thérapeutique.
CA002275438A 1996-11-20 1997-11-19 Methodes ameliorees de transduction cellulaire Abandoned CA2275438A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3133096P 1996-11-20 1996-11-20
US60/031,330 1996-11-20
PCT/US1997/021475 WO1998022605A1 (fr) 1996-11-20 1997-11-19 Methodes ameliorees de transduction cellulaire

Publications (1)

Publication Number Publication Date
CA2275438A1 true CA2275438A1 (fr) 1998-05-28

Family

ID=21858846

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002275438A Abandoned CA2275438A1 (fr) 1996-11-20 1997-11-19 Methodes ameliorees de transduction cellulaire

Country Status (4)

Country Link
EP (1) EP0963440A4 (fr)
JP (1) JP2001505205A (fr)
CA (1) CA2275438A1 (fr)
WO (1) WO1998022605A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004016021A (ja) 2002-06-12 2004-01-22 Japan Science & Technology Corp 抗体および阻害剤並びにそれを用いた形質転換方法および形質転換キット

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5656465A (en) * 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
DE4442587A1 (de) * 1994-11-30 1996-08-01 Boehringer Ingelheim Int Verfahren zum Einbringen von Fremdmaterial in höhere eukaryotische Zellen
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5552309A (en) * 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells

Also Published As

Publication number Publication date
EP0963440A1 (fr) 1999-12-15
WO1998022605A1 (fr) 1998-05-28
EP0963440A4 (fr) 2004-12-29
JP2001505205A (ja) 2001-04-17

Similar Documents

Publication Publication Date Title
CA2518150C (fr) Procedes et compositions impliquant mda-7
Zhang et al. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer.
US20060024780A1 (en) Wwox: a tumor suppressor gene mutated in multiple cancers
JP2005533000A (ja) Ｍｄａ−７に関与する免疫誘導を増強する方法
CN101905024A (zh) 含有血管生成素-样蛋白质3angptl3的组合物及其使用方法
US6251871B1 (en) P16 expression constructs and their application in cancer therapy
US5980886A (en) Recombinant vectors for reconstitution of liver
AU2001267058A1 (en) Aav vector-based compositions and therapeutic uses thereof
WO1998037185A2 (fr) Vecteurs pour expression genique regulee
JP2006094863A (ja) ケモカインα−５
AU762493B2 (en) Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
CA2429769C (fr) Procedes de traitement mettant en application mda-7 humain
WO2002006344A2 (fr) Compositions et procedes a base des proteines vespides et pathogenes associees a des proteines specifiques aux testicules (rtvp) pour le traitement du cancer prostatique
US6517828B1 (en) C-CAM as an angiogenesis inhibitor
CA2275438A1 (fr) Methodes ameliorees de transduction cellulaire
US7052692B1 (en) Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression
WO1998022605A9 (fr) Methodes ameliorees de transduction cellulaire
US6331284B1 (en) P202 is a tumor suppressor
US20060194319A1 (en) Promoter substitution for immunoglobulin therapy
US20010036929A1 (en) Xrcc3 is required for assembly of Rad51-complexes in vivo
US20020169126A1 (en) Compositions and methods for inactivating the Akt oncogene and/or activating the p38 pro-apoptotic gene
WO1999011652A1 (fr) Role de la phosphorylation de la tyrosine d'une proteine cellulaire dans l'expression d'un transgene induit par deux genes d'un virus associe a un adenovirus
AU4435002A (en) Modified retinoblastoma tumor suppressor proteins

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead